{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.75","value":"119.5"},{"groupId":"OG001","spread":"16.73","value":"120.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"887"},{"groupId":"OG001","value":"439"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.03","value":"-4.0"},{"groupId":"OG001","spread":"13.87","value":"-3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"815"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Change at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.82","value":"-4.6"},{"groupId":"OG001","spread":"13.74","value":"-3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"718"},{"groupId":"OG001","value":"329"}],"units":"Participants"}],"title":"Change at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.70","value":"-3.9"},{"groupId":"OG001","spread":"15.71","value":"-5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"621"},{"groupId":"OG001","value":"239"}],"units":"Participants"}],"title":"Change at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.84","value":"-4.0"},{"groupId":"OG001","spread":"15.04","value":"-5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"522"},{"groupId":"OG001","value":"183"}],"units":"Participants"}],"title":"Change at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.01","value":"-4.1"},{"groupId":"OG001","spread":"16.42","value":"-7.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"427"},{"groupId":"OG001","value":"139"}],"units":"Participants"}],"title":"Change at Week 81"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.31","value":"-4.9"},{"groupId":"OG001","spread":"15.80","value":"-5.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"90"}],"units":"Participants"}],"title":"Change at Week 97"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.07","value":"-5.5"},{"groupId":"OG001","spread":"13.16","value":"-5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"title":"Change at Week 113"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.33","value":"-6.3"},{"groupId":"OG001","spread":"13.99","value":"-8.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Change at Week 129"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.75","value":"-5.5"},{"groupId":"OG001","spread":"15.47","value":"-9.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Change at Week 145"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.88","value":"-8.9"},{"groupId":"OG001","spread":"10.95","value":"-7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Change at Week 161"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.19","value":"-4.8"},{"groupId":"OG001","value":"-5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change at Week 177"}],"denoms":[{"counts":[{"groupId":"OG000","value":"933"},{"groupId":"OG001","value":"468"}],"units":"Participants"}],"description":"The FACT-P questionnaire is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess prostate-related symptoms. Each item was rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which ranged from 0 to 156 where higher scores represented better quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 4 capsules of Enzalutamide 40 mg each (total dose 160 mg per day) orally, once daily in double-blind and open-label phase (up to a maximum of 68.8 months) until radiographic progression. Participants after last dose of study drug, were followed up for safety up to 30 days, and were long term followed up (for survival status and new prostate cancer therapies) from last dose to the death date or last known survival date.","id":"OG000","title":"Enzalutamide 160 mg"},{"description":"Participants received 4 capsules of placebo (matched to Enzalutamide) orally, once daily in double blind phase (up to a maximum of 51.3 months) until radiographic progression. Participants were given an opportunity to switch to open-label enzalutamide after completion of double blind phase. Participants after last dose of study drug, were followed up for safety up to 30 days and were long term followed up (for survival status and new prostate cancer therapies) to the death date or last known survival date.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"The ITT population was defined as all participants randomly assigned to study treatment and was based on randomized treatment assignment regardless of whether or not treatment was administered. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177","title":"Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}